Feedback
BD Club Max
×
GBS detection
Sexually-transmitted infection (STI) - June 01, 2021

GBS detection with molecular biology-based method – Bogiel et al.

Add to fav remove to fav Add to favorites Thumb up remove thumb up Like the content

Application of the appropriate molecular biology-based method significantly increases the sensitivity of group B streptococcus detection results

T Bogiel 1, D Depka 2, P Zalas-Więcek 2, M Rzepka 2, E Kruszyńska 3, E Gospodarek-Komkowska 2

June 2021

Abstract:

Background: Streptococcus agalactiae (group B streptococcus: GBS) is a leading cause of early- and late-onset diseases in neonates. Reliable results of GBS carriage investigation among pregnant women may decrease the incidence of neonatal infection and mortality.

Aim: To compare the results of conventional culture investigation with those of the US Food and Drug Administration-approved nucleic acid amplification test (BD MAX™ GBS (Becton Dickinson)), and to establish our own protocols of standard polymerase chain reaction (PCR).

Methods: A total of 250 vaginal-rectal swabs from three different hospitals in Bydgoszcz, Poland, were used to evaluate GBS carriage. Standard laboratory technique (overnight culture in broth enrichment media) results were compared with those of BD MAX™ GBS assay (Becton Dickinson) and two standard PCR protocols, established to detect the cfb and 16S rRNA S. agalactiae genes, from the overnight cultures of the samples in the liquid enrichment media.

Findings: The overall GBS carriage was estimated as 16.4-23.2%, depending on the applied detection method. The highest percentage of positive results, from each laboratory was obtained with the application of BD MAX™ GBS assay. The differences in the number of positive results obtained with this particular method were statistically significant. Overall, 27 discrepancies were noted for the results obtained with the application of the methods compared.

Conclusions: The methods applied for GBS detection differ in sensitivity. A culture technique, though very specific, appears to be less sensitive at detecting S. agalactiae compared with the commercially available BD MAX™ GBS assay or in-house PCR protocols established for this purpose.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Access the full publication

By reading this content you are acknowledging our forward looking statement.

Why join BD MAX™ Club?

Connect with professionals from around the world BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.

Tailored medical and technical expertise Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Log in to your BD MAX™ Club account anywhere, anytime to access our information database.

Exclusive members’ perks BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.

Join BD MAX™ Club

More scientific content

How can BD MAX™ Club support your lab’s challenges?

All topics

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.

All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.